EP3532051A4 - Kleinmolekülige protein-arginin-methyltransferase 5 (prmt5)-inhibitoren und verfahren zur behandlung - Google Patents

Kleinmolekülige protein-arginin-methyltransferase 5 (prmt5)-inhibitoren und verfahren zur behandlung Download PDF

Info

Publication number
EP3532051A4
EP3532051A4 EP17863518.1A EP17863518A EP3532051A4 EP 3532051 A4 EP3532051 A4 EP 3532051A4 EP 17863518 A EP17863518 A EP 17863518A EP 3532051 A4 EP3532051 A4 EP 3532051A4
Authority
EP
European Patent Office
Prior art keywords
prmt5
inhibitors
treatment
methods
small molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17863518.1A
Other languages
English (en)
French (fr)
Other versions
EP3532051A1 (de
Inventor
Tao Lu
Lakshmi Milind PRABHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University
Original Assignee
Indiana University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University filed Critical Indiana University
Publication of EP3532051A1 publication Critical patent/EP3532051A1/de
Publication of EP3532051A4 publication Critical patent/EP3532051A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP17863518.1A 2016-10-26 2017-10-26 Kleinmolekülige protein-arginin-methyltransferase 5 (prmt5)-inhibitoren und verfahren zur behandlung Pending EP3532051A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662413341P 2016-10-26 2016-10-26
US201762534969P 2017-07-20 2017-07-20
PCT/US2017/058572 WO2018081451A1 (en) 2016-10-26 2017-10-26 Small molecule protein arginine methyltransferase 5 (prmt5) inhibitors and methods of treatment

Publications (2)

Publication Number Publication Date
EP3532051A1 EP3532051A1 (de) 2019-09-04
EP3532051A4 true EP3532051A4 (de) 2020-08-12

Family

ID=62025487

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17863518.1A Pending EP3532051A4 (de) 2016-10-26 2017-10-26 Kleinmolekülige protein-arginin-methyltransferase 5 (prmt5)-inhibitoren und verfahren zur behandlung

Country Status (4)

Country Link
US (3) US11034689B2 (de)
EP (1) EP3532051A4 (de)
CN (1) CN110325188A (de)
WO (1) WO2018081451A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108689960B (zh) * 2018-06-07 2022-03-04 济南大学 5-苯亚甲基-2-苯基噻唑酮类化合物及其制备和应用
CN111686113B (zh) * 2019-03-15 2022-12-30 北京大学 Sonic Hedgehog抑制剂及应用
WO2020206289A1 (en) * 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
WO2020206299A1 (en) * 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
GB201908885D0 (en) * 2019-06-20 2019-08-07 Storm Therapeutics Ltd Therapeutic compounds
EP4084871A4 (de) * 2019-12-31 2024-01-24 Univ Indiana Trustees Wiederverwendung von fda-zugelassenen medikamenten als neue krebstherapie durch hemmung von prmt5
US20230025976A1 (en) * 2020-01-07 2023-01-26 Pfizer Inc. PRMT5 Inhibitor for Use In A Method of Treating Psoriasis and Other Autoimmune Conditions
WO2022002142A1 (zh) * 2020-06-30 2022-01-06 江苏先声药业有限公司 四氢异喹啉类化合物及其用途
CN112831521B (zh) * 2021-02-02 2022-07-05 中国人民解放军军事科学院军事医学研究院 一种扩张型心肌病小鼠模型的构建方法及其应用
CN115124534B (zh) * 2021-11-23 2023-09-15 中山大学 非核苷酸类prmt5小分子抑制剂、制备方法及用途
US20230181589A1 (en) * 2021-12-03 2023-06-15 The Trustees Of Indiana University Prmt5 inhibitors for ocular therapy
WO2023125947A1 (zh) * 2021-12-30 2023-07-06 江苏先声药业有限公司 四氢异喹啉类化合物的可药用盐、晶型及其用途
CN114366813A (zh) * 2022-01-21 2022-04-19 中南大学 一种治疗肿瘤的靶点及其应用、肿瘤治疗制剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016145150A2 (en) * 2015-03-11 2016-09-15 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064947A (en) * 1989-03-29 1991-11-12 Merrell Dow Pharmaceuticals Inc. Selective adenosine reseptor compounds
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US6218387B1 (en) 1996-12-20 2001-04-17 Hoechst Aktiengesellschaft Vitronectin receptor anatagonists, their preparation and their use
EP1149583A3 (de) 2000-04-13 2001-11-14 Pfizer Products Inc. Kombinationen bestehend aus Antagonisten des Corticotropin freisetzenden Faktors und Stoffen, die die Wachstumshormonsekretion fördern
TW200400034A (en) * 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
CA2619365A1 (en) 2005-08-22 2007-03-01 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
GB0522880D0 (en) 2005-11-09 2005-12-21 Glaxo Group Ltd Novel compounds
JP2012503613A (ja) * 2008-09-25 2012-02-09 ラシオファルム ゲーエムベーハー コンパクト化シナカルセット
WO2012009258A2 (en) * 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016145150A2 (en) * 2015-03-11 2016-09-15 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHENG C C ET AL: "Potential Purine Antagonists. XII. Synthesis of 1-Alkyl(aryl)-4,6-disubstituted Pyrazolo[3,4-d]pyrimidines", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 23, 1 June 1958 (1958-06-01), pages 852 - 861, XP002385022, ISSN: 0022-3263, DOI: 10.1021/JO01100A025 *
ELAYNE CHAN-PENEBRE ET AL: "A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models", NATURE CHEMICAL BIOLOGY, vol. 11, no. 6, 27 April 2015 (2015-04-27), Basingstoke, pages 432 - 437, XP055297240, ISSN: 1552-4450, DOI: 10.1038/nchembio.1810 *
GUI-MEI KONG ET AL: "Selective small-chemical inhibitors of protein arginine methyltransferase 5 with anti-lung cancer activity", PLOS ONE, vol. 12, no. 8, 14 August 2017 (2017-08-14), pages 1 - 23, XP055673216, DOI: 10.1371/journal.pone.0181601 *
KEITARO SENGA ET AL: "Synthesis and xanthine oxidase inhibitory activity of 4,6-disubstituted 1- p -chlorophenylpyrazolo[3,4- d ]pyrimidines", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 19, no. 6, 1 November 1982 (1982-11-01), pages 1565 - 1567, XP055117070, ISSN: 0022-152X, DOI: 10.1002/jhet.5570190666 *
MURTY DEVARAKONDA ET AL: "Synthesis of novel 2-alkyl-4-substituted-amino-pyrazolo[3,4-d]pyrimidines as new leads for anti-bacterial and anti-cancer activity", MEDICINAL CHEMISTRY RESEARCH., vol. 22, no. 3, 4 June 2012 (2012-06-04), US, pages 1090 - 1101, XP055673495, ISSN: 1054-2523, DOI: 10.1007/s00044-012-0084-0 *
See also references of WO2018081451A1 *

Also Published As

Publication number Publication date
WO2018081451A1 (en) 2018-05-03
EP3532051A1 (de) 2019-09-04
US20200062745A1 (en) 2020-02-27
US20210269431A1 (en) 2021-09-02
CN110325188A (zh) 2019-10-11
US11034689B2 (en) 2021-06-15
US20240083894A1 (en) 2024-03-14

Similar Documents

Publication Publication Date Title
EP3532051A4 (de) Kleinmolekülige protein-arginin-methyltransferase 5 (prmt5)-inhibitoren und verfahren zur behandlung
IL272519B (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EP3761978A4 (de) Inhibitoren der protein-arginin-methyltransferase 5 (prmt5), pharmazeutische produkte davon und verfahren dafür
EP3700527A4 (de) Papd5-inhibitoren und verfahren zur verwendung davon
EP3589291A4 (de) Zusammensetzungen und verfahren zur hemmung von zelllinienspezifischen proteinen
EP3429591A4 (de) Substituierte inhibitoren von menin-mll und verfahren zur verwendung
EP3454945A4 (de) Ash11-inhibitoren und verfahren zur behandlung damit
EP3270917A4 (de) Verbindungen und verfahren zum verbesserten abbau von zielproteinen
EP3510040A4 (de) Ektonukleotidasehemmer und verfahren zur verwendung davon
EP3509590A4 (de) N-acyl-aminosäure-verbindungen und verfahren zur verwendung
EP3234200A4 (de) Zusammensetzungen und verfahren zur gezielten abreicherung, anreicherung und aufteilung von nukleinsäuren unter verwendung von crispr/cas-systemproteinen
EP3558998A4 (de) Ektonukleotidasehemmer und verfahren zur verwendung davon
EP3558303A4 (de) Aminosäureverbindungen und verfahren zur verwendung
EP3755317A4 (de) Verbindungen zum abbau / zur zerstörung von protein-arginin-methyltransferase 5 (prmt5) und verwendungsverfahren
EP3619210A4 (de) Inhibitoren von niedermolekularer protein-tyrosinphosphatase (lmptp) und verwendungen davon
EP3142652A4 (de) Heterocyclische hydroxamsäure als proteindeacetylaseinhibitoren und duale proteindeacetylase-proteinkinase-inhibitoren und verfahren zur verwendung davon
EP3706737A4 (de) Ash11-inhibitoren und verfahren zur behandlung damit
EP3952874A4 (de) Selektive inhibitoren der protein-arginin-methyltransferase 5
EP3710430A4 (de) Acss2-hemmer und verfahren zur verwendung
EP3946352A4 (de) Selektive inhibitoren der protein-arginin-methyltransferase 5
EP3303366A4 (de) Derivate von dolastatin 10 und verwendungen davon
EP3515449A4 (de) Chromoboxproteinhemmer und verwendungen davon
IL277263A (en) Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
EP3746430A4 (de) Inhibitoren von protein-arginin-deiminasen
EP3414555A4 (de) Verfahren und zusammensetzung zur schnellen detektion von proteinrückständen

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190524

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE TRUSTEES OF INDIANA UNIVERSITY

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 43/23 20060101ALI20200401BHEP

Ipc: A61P 35/00 20060101ALI20200401BHEP

Ipc: A61K 31/4439 20060101ALI20200401BHEP

Ipc: C07D 453/02 20060101ALI20200401BHEP

Ipc: A61K 31/416 20060101ALI20200401BHEP

Ipc: C07D 487/04 20060101AFI20200401BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20200710

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 43/23 20060101ALI20200706BHEP

Ipc: C07D 453/02 20060101ALI20200706BHEP

Ipc: A61P 35/00 20060101ALI20200706BHEP

Ipc: C07D 487/04 20060101AFI20200706BHEP

Ipc: A61K 31/416 20060101ALI20200706BHEP

Ipc: A61K 31/4439 20060101ALI20200706BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210426

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS